Milestone Pharmaceuticals Inc
MIST1.760USD
+0.040+2.33%
終値 02/06, 16:00（ET）15分遅れの株価
149.90M時価総額
損失額直近12ヶ月PER
詳細情報 Milestone Pharmaceuticals Inc 企業名
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Incの企業情報
企業コードMIST
会社名Milestone Pharmaceuticals Inc
上場日May 09, 2019
最高経営責任者「CEO」Oliveto (Joseph)
従業員数33
証券種類Ordinary Share
決算期末May 09
本社所在地420-1111 boul. Dr.-Frederik-Philips
都市MONTREAL
証券取引所NASDAQ OMX - NASDAQ BASIC
国Canada
郵便番号H4M 2X6
電話番号15143360444
ウェブサイトhttps://www.milestonepharma.com
企業コードMIST
上場日May 09, 2019
最高経営責任者「CEO」Oliveto (Joseph)
Milestone Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+7855.00%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+7855.00%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+50000.00%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Mr. Jeffrey Nelson
Mr. Jeffrey Nelson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+7855.00%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+7855.00%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+50000.00%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Propel Bio Management, LLC
6.02%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
他の
68.16%
株主統計
株主統計
比率
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Propel Bio Management, LLC
6.02%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
他の
68.16%
種類
株主統計
比率
Investment Advisor
16.52%
Hedge Fund
14.43%
Venture Capital
6.24%
Research Firm
5.04%
Individual Investor
3.97%
Investment Advisor/Hedge Fund
3.95%
Private Equity
3.78%
Family Office
1.17%
Bank and Trust
0.02%
他の
44.87%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
118
42.48M
49.88%
+14.49M
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Simplify Asset Management Inc
7.96M
9.34%
+5.18M
+186.09%
Sep 30, 2025
Adage Capital Management, L.P.
6.98M
8.19%
+6.98M
--
Sep 30, 2025
Propel Bio Management, LLC
5.12M
6.02%
+4.27M
+502.93%
Jul 11, 2025
Trails Edge Capital Partners LP
3.83M
4.5%
-1.50M
-28.13%
Sep 30, 2025
OrbiMed Advisors, LLC
3.22M
3.78%
+3.22M
--
Sep 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
Morgan Stanley & Co. LLC
2.63M
3.09%
+1.81M
+221.87%
Sep 30, 2025
RTW Investments L.P.
2.51M
2.94%
--
--
Sep 30, 2025
Pathstone
1.00M
1.17%
+1.00M
--
Sep 30, 2025
Two Sigma Investments, LP
900.59K
1.06%
+900.59K
--
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
比率8.04%
SPDR S&P International Small Cap ETF
比率0.01%
Avantis US Small Cap Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
